Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Graft Versus Host Disease, Hodgkin's Disease, Myelodysplastic Syndromes, Non-Hodgkin's Lymphoma
Conditions
Keywords
Graft versus Host Disease, GVHD, sirolimus, tacrolimus, Stem cell transplant
Brief summary
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from an unrelated donor. This trial is designed to test the hypothesis that elimination of methotrexate in the unrelated donor group would lead to less transplant-related toxicity while still preserving the effective control of GVHD.
Detailed description
* Therapy to prevent GVHD will consist of an infusion of tacrolimus intravenously and sirolimus orally once daily starting 3 days before stem cell infusion. This will take place in the hospital where the patient will remain for the duration of the transplant. * Sirolimus will continue for approximately 100 days at a stable dose, then it will be tapered slowly over the course of weeks to months to prevent a flare in GVHD. * Patients will be seen in the clinic weekly for the first 2 months after discharge from the hospital. If GVHD is present, tapering schedule will be slower and based on the patient's clinical condition. * Tacrolimus will also be given orally after the patient is discharged and will be tapered on the same schedule as sirolimus. * During the year following stem cell transplant, blood tests will be performed to evaluate the immune system and graft versus host disease.
Interventions
DRUGsirolimus
DRUGtacrolimus
Sponsors
Dana-Farber Cancer Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Acute myelogenous leukemia(AML) in first or subsequent remission, in untreated first relapse or any treated relapse. * Acute lymphoblastic leukemia(ALL) in first or subsequent remission, in untreated first relapse or any treated relapse. * Chronic myelogenous leukemia in first or second chronic stable phase or in accelerated phase. * Myelodysplastic syndromes or myeloproliferative diseases * Non-Hodgkin's lymphoma or Hodgkin's disease in second or greater complete remission, in partial remission, or induction failure. * Chronic lymphocytic leukemia, Rai stage 2-4, which has progressed after initial therapy. * Matched unrelated donor. * Age 18-55 years at the time of stem cell transplantation * ECOG performance status 0-2 * Life expectancy of 100 days without stem cell transplantation * Total bilirubin \< 2.0 mg/dl * AST \< 90 IU * Serum creatinine \< 2.0 mg/dl * Ejection fraction \> 40% by echocardiogram or gated nuclear medicine study.
Exclusion criteria
* Uncontrolled infection * Forced vital capacity or DLCO \< 50% predicted for age * Uncontrolled hypertension * Prior hematopoietic stem cell transplant * Evidence of HIV infection or active Hepatitis B or C infection * Cholesterol \> 300 mg/dl * Relapsed aggressive Burkitt's or Burkitt's-like lymphoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the feasibility of using a combination of sirolimus and tacrolimus without methotrexate for GVHD prophylaxis after stem cell transplantation. | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the rates of grade II-IV and III-IV acute GVHD with historical control | — |
| to determine the incidence of 100 day mortality using this GVHD prophylaxis regimen | — |
| to determine the overall survival after one year of this patient population. | — |
Countries
United States
Outcome results
None listed